We aimed to assess the pharmacokinetics of vancomycin in critically ill infants, and to evaluate the standard recommended dose oJ 10 mglkg 6 hourly.
Infants in intensive care units (ICUs) are at risk of gram-positive nosocomial infections. This risk is increased by the many tubes and catheters used in ICU which breach the skin and mucosal barriers. As elsewhereI, methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE) are significant pathogens in our unit and vancomycin is prescribed frequently for these ICU-acquired infections.
Several studies have described the relationship between vancomycin clearance and post-conceptional age in preterm neonates 2 .". Dose requirements have not been clarified for critically ill older children, i.e. infants. We therefore question whether the dosages recommended by the manufacturers for babies over one month"", i.e. 10 mg/kg 6 hrIy or 40 mg/kg day, are correct and whether they would provide therapeutic serum concentrations for these patients.
This study was designed to assess the pharmacokinetics of vancomycin in critically ill infants, in an attempt to evaluate the recommended dose in these patients.
SUBJECTS AND METHOD
Following approval by the Ethical Committee of the University of the Witwatersrand, the study was conducted in the Baragwanath Hospital I Cv. Infants aged 1 to 10 months, for whom vancomycin was prescribed and who had arterial lines in situ, were prospectively enrolled after obtaining written informed consent from their parents, All patients received vancomycin for a proven or suspected methicillinresistant staphylococcal infection. Patients with known hypersensitivity to vancomycin or renal insufficiency (initial serum creatinine> 100 JLmoIll) were excluded. Every patient had a daily measurement of serum urea and creatinine throughout the study, No patient experienced an increase in serum creatinine after enrolment.
All infants received vancomycin at 10 mg/k g 6 hrIy throughout the course, Vancomycin was diluted to 5 mg/ml with normal saline or 5070 glucose and administered over 60 minutes. Vancomycin infusions were supervised by one investigator (JS).
Blood samples for pharmacokinetic evaluation were taken from the arterial line, immediately before the infusion, at 30, 60, 120 and 300 minutes post infusion. The series of samples were taken on days 2 and 8 of therapy. We consider the day of commencement of therapy as day 0, therefore the serum concentrations on days 2 and 8 reflect the concentrations after 3 and 9 days of therapy respectively. Blood samples were centrifuged for 5 minutes at 4500 revolutions per minute. All samples for a particular day were analysed as a batch by fluorescence polarization immunoassay (Cobas Fara 11, Roche Diagnostics, Isando, South Africa) in the Therapeutic Drug Monitoring laboratory of Baragwanath Hospital.
Data Analysis
Serum drug concentrations were plotted graphically to determine the distribution and elimination phases. Serum concentrations taken 120 minutes post infusion were shown to be in the elimination phase, and therefore these values were used to determine the pharmacokinetic parameters. The elimination rate constant (k e1 ) was calculated from the natural log quotient of the measured levels at 120 and 300 minutes divided by the time difference between the two levels. The elimination half-life (t Y2 e l) was calculated by the standard equation: t Yzel =0.693/k e1 • The peak concentration (Cmax) was determined by back-extrapolation from the serum concentration taken 120 minutes post infusion, to the extrapolated peak at the end of the infusion using the equation: C(O) = C/ekt. The serum concentration at 300 minutes post infusion was used as the trough concentration (Cmin). The apparent volume of distribution (Vd) was calculated according to the Sawchuk-Zaske method'. This method seems to be an appropriate and reliable method to calculate Vd and optimize vancomycin therapy in the clinical settingS, provided that the peak serum concentration is not taken during the distribution phase. Although it is known that vancomycin elimination follows a triexponential patternS, it has limited influence at steady state on a six-hourly interval, and therefore a one compartment kinetic model can be used for pharmacokinetic calculations. Total clearance (CL) was calculated as the actual dose administered divided by the area under the time-concentration graph (AUC) using the trapezoid rule.
Statistical Analysis
Pharmacokinetic variables obtained on the two study days (days 2 and 8) were compared using the paired Anaesthesia and Intensive Care, Vol. 23 Hest. Statgraphics 6.0 (Statistical Graphics Corporation, Cambridge MA) software package was used.
A P-value < 0.05 was regarded as significant.
RESULTS
Vancomycin serum concentrations were performed on 20 patients of whom 17 survived and three died. Two patients were discharged before day 8. Therefore pharmacokinetic profiles for both study days were available on 15 patients. Demographic data for the patients are shown in Table 1 . The serum creatinine values on days 0, 2 and 8 are presented in Table 2 . Table 3 shows the results of the pharmacokinetic studies. On days 2 and 8, respectively, 53% and 27% of the patients had a Cmin within the therapeutic range of our institution. Cmax was therapeutic in 53% and 60% respectively for the two study days. The therapeutic range in our institution is 5-10 flg/ml for the trough concentration and a peak concentration of 25-40 flg/ml. None of the patients however had both Cmin and Cmax within the therapeutic range. Patients no. 7, 10 and 15 required more aggressive fluid replacement therapy in the early stages of their treatment, which probably resulted in the very large Vd. The t V2 e l of these three patients were also prolonged but both the Vd and t V2 e l were relatively normal on day 8. Table 4 shows the mean (SD) values for Cmin, Cmax, Vd, tYzel and CL obtained on days :2 and 8 for the 15 patients who had both profiles measured. The mean Cmax was lower on day 2 than on day 8 (29.l ± 12.0 p.g/ml and 35.5 ± ILl p.g/ml respectively, P=0.02). The range of Cmax on day 2 (11-64.8 p.g/ml) was much wider than that of day 8 (17.5-53.3 mg/ml). The mean Vd was almost twice as large on day 2 (0.81 IIkg) than on day 8 (0.44 IIkg). In addition, the mean t Yzel decreased from 5.3h to 3.4h over the treatment period. Mean Cmin, CL and serum creatinine did not change significantly from day 2 to day 8.
DISCUSSION
Critically ill patients experience fluid losses from the intravascular space as a result of various factors such as vascular permeability and inflammatory processes 9 -12
• In this clinical setting, resuscitation and vigorous replacement of fluid losses will be associated with an increase in extravascular volume. This will increase the Vd. Therefore pharmacokinetic parameters will differ between critically ill patients, less severely ill patients and healthy volunteers. This has been The Vd of 15 patients, for whom we obtained serum concentrations on both days 2 and 8, was significantly higher initially and decreased over the treatment period. This is in keeping with some previously published data on other drugs. Triginer et a1'3 showed that gentamicin Vd was increased in septic patients, and returned to normal when physiological changes due to sepsis had been corrected. Reed et all' showed an initial increase in amikacin Vd in trauma patients. It has been shown further that patients with burns and intravenous drug abusers have an increased Vd and CL of vancomycin 17.
TABLE 3
Actual values obtained in 20 patients on day 2. and 15 patients on day 8 Critically ill patients with sepsis or trauma burns all require aggressive fluid resuscitation due to the systemic inflammatory response. Because the Vd is not a true volume but an apparent volume it will be influenced by all the fluid administered to the patient. This leads to expansion of the extracellular volume and therefore routine doses of gentamicin, amikacin and vancomycin may not provide therapeutic serum concentrations.
Any changes in Vd and CL, both being independent pharmacokinetic parameters, will have an effect on other dependent pharmacokinetic parameters, i.e. serum concentrations, t Y1 e l' In our study the CL did not change between the two study days. Therefore the change in Vd contributes to the changes in Cmax and t Y1el' The mean Cmax was significantly lower on day 2 (29.1 ± 12.0 ftg/ml) than on day 8 (35.5 ±11.1 ~/ml). Although there are no clinical studies to analyse a direct effect of serum concentrations and outcome, Lisby-Sutch and co-workers4 showed that peak serum concentrations of 25-35 ftg/ml (with trough concentrations of 5-10 ftg/ml) had good serum inhibitory and bactericidal titres and produce good activity against staphylococci. The lack of correlation between serum concentrations and outcome is further clouded by the inconsistency in the literature with regard to the timing of peak values I8 . 19 . Leonard et apo used the measured peak at the end of a 60 minute infusion. We, as well as othersI9.21.22 extrapolated back from samples taken during the elimination phase, 1 to 3 hours after an infusion to calculate "true peaks" and some 4 . 23 did not specify which peaks they had used. Although mean Cmax in our patients was therapeutic, only 50070 of all patients on day 2 had therapeutic peak serum concentrations of 25 to 35 mg/ml as suggested by the literature'·20. 24 . In contrast, 80070 of the patients on day 8 had therapeutic peak serum concentrations with a 40 mg/kg/day dosage regimen. We stress that the increase in Cmax over this period was related to the decrease in Vd of vancomycin.
The routine monitoring of vancomycin serum concentrations is common practice but the validity and the need for it is questionableI8.2l.27. The limited value of routine monitoring is based on the lack of adequate data to support a correlation between serum concentrations, therapeutic outcome and toxicity. Dosing recommendations should therefore be based on the age, weight and renal function of patientsI8.26.27.
The ranges (Table 3 ) that were obtained, on the dose of 10 mg/kg six-hourly, for Cmin and Cmax on day 8 are very similar to the Cmin (3-19 ftg/ml) and Cmax (18-57 ftg/ml) obtained by Schaad et aP8. The ranges on day 2, however, were wider due to the wide range in Vd as discussed above. The dosing recommendations do not take a change in Vd into account. If one uses the Sawchuk-Zaske method" which takes the Vd into account, to calculate doses, a dose of 50 to 60 mg/kg/day (in divided doses) is needed to achieve peak serum concentrations above 25 ftg/ml in 800/0 of our patients on day 2.
Nephrotoxicity has been reported to be a side-effect of vancomycin therapy in 5 to 15070 of patients 23 . 29 . A higher incidence of nephrotoxicity has been described in patients who had vancomycin trough concentrations greater than 10 ftg/mp3. In this study the mean Cmin on days 2 and 8 were above the recommended range in 47070 and 54070 of patients respectively. A rise in serum creatinine of more than 50070 from the baseline has been used as a marker of nephrotoxicity23.24. Patient no. 13 had an increase of 55070 in serum creatinine although Cmin was less than 10 ftg/ml on both study days. Two other patients (no. 1, 4) had an increase of 42070 and 43070 respectively. All three of these patients received amikacin either prior to or concurrent with vancomycin. We believe therefore that vancomycin therapy cannot be implicated as the sole cause of the decrease in renal function.
CONCLUSION
In critically ill infants we have shown a large volume of distribution of vancomycin early in the septic episode, which changed significantly over the treatment period. The clearance of the drug, however, remained the same. Our study further shows that for the standard (quoted) dose of vancomycin (10 mg/kg/day q6h) the initial range of serum concentrations is wider than that reported in the literature.
Although the routine monitoring of vancomycin serum concentrations still remains controversial we feel that it is indicated in critically ill infants who have altered pharmacokinetics for the reasons mentioned above. Further clinical studies however are necessary to establish a relationship between serum concentrations and bacteriological cure and outcome.
